1Conen D, Osswald S, Albert CM. Epidemiology of atrial fibrillation [ J). Swiss Med Wkly,2009 ; 139 (25/26) :346-52.
2Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation [ J ]. Med Clin North Am,2008 ; 92 ( 1 ) : 17-40.
3Turhan H, Aksoy Y, Yetkin E, et al. The impact of inflammation on the development, successful cardioversion, recurrence and/or perpetuation of atrial fibrillation[ J]. Int J Cardiol,2007 ;118(2) :256-7.
5Bruins P, Velthuis H, Yazdanbakhsi, AP, et al. Activation of the comple- ment system during and after cardiopuhnonary bypass surgery:postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia[J]. Circulation, 1997 ;96 (10) :3542-8.
6Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation[ J]. Circulation, 1997 ;96 (4) :1180-4.
7Kourliouros A, Savelieva I, Kiotsekoglou A, et al. Current concepts in the pathogenesis of atrial fibrillation[J]. Am Heart J, 2009 ; 157 ( 2 ) : 243- 52.
8L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation [ J ]. J Am Coll Cardiol, 2004,44:159.
9Wachtell K, Lehto M, Gerdts E, et al. Angiotensin-Ⅱ receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study [ J ]. J Am Coll Cardiol, 2005,45:712.
10Pedersen OD, Bagger H, Kober L, et al. Trandopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction [ J ]. Circulation, 1999, 100 : 376.
4L6vy S,Camm AJ,Saksena S,et al. International consensus on no-menclature and classification of atrial fibrillation: a collaborativeproject of the working group on arrhythmias and the working groupof cardiac pacing of the european society of cardiology and the northamerican society of pacing and electrophysiology. J CardiovascElectrophysiol,2003,14(4) :443-445.
5Christensen AL,Rasmussen LH,Baker MG,et al. Seasonality,in-cidence and prognosis in atrial fibrillation and stroke in Denmarkand New Zealand. BMJ Open,2012,2(4) :1136-1146.
6Cardin S,Li D,Trescases N,et al. Evolution of the atrial fibrilla-tion substrate in experimental congestive heart failure : angioten-sin-dependent and independent pathways. Cardiovasc Res, 2003,60(2) :315-325.
7Yoshizaki T,Umetani K,Ino Y,et al. Activated inilammation is re-lated to the incidence of atrial fibrillation in patients with acutemyocardial infarction. Intern Med,2012,51(12) : 1467-1471.
8Kim BJ,Hwang SJ,Sung KC,et al. Assessment of factors affectingplasma BNP levels in patients with chronic atrial fibrillation andpreserved left ventricular systolic function. Int J Cardiol,2007,118(2) ;145-150.
9Barassi A, Pezzilli R, Morselli-Labate AM, et al. Serum amyloidaand C-reactive protein independently predict the recurrences ofatrial fibrillation after cardioversion in patients with preserved leftventricular function. Can J Cardiol,2012,5(2) :327-330.
